Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients.
Kerman
R H
RH
Department of Surgery, University of Texas Medical School, Houston 77030.
Van Buren
C T
CT
Lewis
R M
RM
Kahan
B D
BD
D001379:Azathioprine / Q000627:therapeutic use; D001803:Blood Transfusion; D002102:Cadaver; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000627:therapeutic use*; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006681:HLA-D Antigens / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation; D011241:Prednisone / Q000627:therapeutic use; D012307:Risk Factors
D003524:Cyclosporins; D006680:HLA Antigens; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D007518:Isoantibodies; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone